These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 26527872)
1. Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity. Guada M; Sebastián V; Irusta S; Feijoó E; Dios-Viéitez Mdel C; Blanco-Prieto MJ Int J Nanomedicine; 2015; 10():6541-53. PubMed ID: 26527872 [TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies. Guada M; Lasa-Saracíbar B; Lana H; Dios-Viéitez Mdel C; Blanco-Prieto MJ Int J Pharm; 2016 Mar; 500(1-2):154-61. PubMed ID: 26794875 [TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation. Guada M; Lana H; Gil AG; Dios-Viéitez Mdel C; Blanco-Prieto MJ Eur J Pharm Biopharm; 2016 Apr; 101():112-8. PubMed ID: 26877154 [TBL] [Abstract][Full Text] [Related]
4. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. Sandri G; Bonferoni MC; Gökçe EH; Ferrari F; Rossi S; Patrini M; Caramella C J Microencapsul; 2010; 27(8):735-46. PubMed ID: 21034366 [TBL] [Abstract][Full Text] [Related]
5. Technology of stable, prolonged-release eye-drops containing Cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM). Wolska E; Sznitowska M Int J Pharm; 2013 Jan; 441(1-2):449-57. PubMed ID: 23164704 [TBL] [Abstract][Full Text] [Related]
6. Cyclosporine a loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization. Varia JK; Dodiya SS; Sawant KK Curr Drug Deliv; 2008 Jan; 5(1):64-9. PubMed ID: 18220553 [TBL] [Abstract][Full Text] [Related]
7. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Dudhipala N; Veerabrahma K Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287 [TBL] [Abstract][Full Text] [Related]
8. Stability of lipid excipients in solid lipid nanoparticles. Radomska-Soukharev A Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589 [TBL] [Abstract][Full Text] [Related]
9. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. Hirunpanich V; Sato H Eur J Pharm Biopharm; 2009 Oct; 73(2):247-52. PubMed ID: 19560537 [TBL] [Abstract][Full Text] [Related]
10. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Shete H; Patravale V Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345 [TBL] [Abstract][Full Text] [Related]
11. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442 [TBL] [Abstract][Full Text] [Related]
12. New nano-matrix oral formulation of nanoprecipitated cyclosporine A prepared with multi-inlet vortex mixer. Suzuki H; Hamao S; Seto Y; Sato H; Wong J; Prud'homme RK; Chan HK; Onoue S Int J Pharm; 2017 Jan; 516(1-2):116-119. PubMed ID: 27845213 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity and anti-inflammatory activity of cyclosporine A loaded PLGA nanoparticles for ocular use. Hermans K; Van Den Plas D; Schreurs E; Weyenberg W; Ludwig A Pharmazie; 2014 Jan; 69(1):32-7. PubMed ID: 24601220 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. Onoue S; Sato H; Kawabata Y; Mizumoto T; Hashimoto N; Yamada S J Control Release; 2009 Aug; 138(1):16-23. PubMed ID: 19376169 [TBL] [Abstract][Full Text] [Related]
15. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Chen X; Young TJ; Sarkari M; Williams RO; Johnston KP Int J Pharm; 2002 Aug; 242(1-2):3-14. PubMed ID: 12176220 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. Başaran E; Demirel M; Sirmagül B; Yazan Y J Microencapsul; 2010; 27(1):37-47. PubMed ID: 19545226 [TBL] [Abstract][Full Text] [Related]
17. Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles. Leung SS; Wong J; Guerra HV; Samnick K; Prud'homme RK; Chan HK AAPS J; 2017 Mar; 19(2):578-586. PubMed ID: 28070713 [TBL] [Abstract][Full Text] [Related]
18. In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug. Rasul A; Imran Khan M; Ur Rehman M; Abbas G; Aslam N; Ahmad S; Abbas K; Akhtar Shah P; Iqbal M; Ahmed Al Subari AM; Shaheer T; Shah S Int J Nanomedicine; 2020; 15():7937-7949. PubMed ID: 33116510 [TBL] [Abstract][Full Text] [Related]
19. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Kim ST; Jang DJ; Kim JH; Park JY; Lim JS; Lee SY; Lee KM; Lim SJ; Kim CK Pharmazie; 2009 Aug; 64(8):510-4. PubMed ID: 19746839 [TBL] [Abstract][Full Text] [Related]
20. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats. Yang ZQ; Xu J; Pan P; Zhang XN Pharmazie; 2009 Jan; 64(1):26-31. PubMed ID: 19216227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]